Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 954 |
| INN | Remternetug |
| Status | Clinical |
| Drug code(s) | LY3372993 |
| Brand name | None |
| mAb sequence source | mAb human |
| General Molecular Category | Naked monospecific |
| Format, general category | Full length Ab |
| Format details | None |
| Isotype (Fc) | IgG1 |
| Light chain isotype | kappa |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | None |
| Target(s) | Amyloid beta (N3pG) |
| Indications of clinical studies | Alzheimer disease |
| Primary therapeutic area | Neurological disorders |
| Most advanced stage of development (global) | Phase 3 |
| Status | Active |
| Start of clinical phase (IND filing or first Phase 1) | November 15, 2018 |
| Start of Phase 2 | |
| Start of Phase 3 | August 01, 2022 |
| Date BLA/NDA submitted to FDA | |
| Year of first approval (global) | None |
| Date of first US approval | |
| INN, US product name | None |
| US or EU approved indications | None |
| Company | Eli Lilly and Company |
| Licensee/Partner | None |
| Comments about company or candidate | NCT06653153 Phase 3 in AD due to start in Oct 2024. NCT06647498 Phase 2/3 in AD due to start in Nov 2024. NCT05463731 Phase 3 started in Aug 2022 is recruiting as of last update on May 17, 2023. NCT04451408 Phase 1 started in July 2020; NCT03720548 Phase 1 started in Nov 2018. |
| Full address of company | Indianapolis, Indiana, United States North America United States of America https://www.lilly.com/contact-us |
Described as a monoclonal antibody in: Cummings, J., Lee, G., Ritter, A., Sabbagh, M., Zhong, K. (2019). Alzheimer's Disease Drug Development Pipeline: 2019. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 5 272-293. Elsevier. http://dx.doi.org/10.1016/j.trci.2019.05.008 Remternetug (LY3372993) is an IgG1 monoclonal antibody directed at the pyroglutamate modification of the third amino acid of amyloid-beta peptide that is present only in brain amyloid plaques https://assets.ctfassets.net/mpejy6umgthp/51Sv0wOrFxfiHJNqcyuNYu/0c5df804e8a23256262fcb40489ae181/REMIPT3_ADPD2023_JIN_SAFETY_PLAQUE_REDUCTION_Ph1LAKB.pdf
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |